Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-CalPRNewsWire • 03/20/24
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended PregnancyPRNewsWire • 03/07/24
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023PRNewsWire • 02/01/24
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology ApplicationsBusiness Wire • 01/30/24
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 MillionBusiness Wire • 01/08/24
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness Wire • 01/05/24
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness Wire • 12/29/23
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFMBusiness Wire • 12/18/23
ADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to ShareholdersBusiness Wire • 12/12/23
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women GloballyBusiness Wire • 12/12/23
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me PlatformBusiness Wire • 10/05/23
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023Business Wire • 09/08/23
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness Wire • 09/06/23
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness Wire • 08/31/23
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial ScaleBusiness Wire • 08/18/23
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023Business Wire • 08/17/23
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023Business Wire • 08/17/23